Skip to main content
Clinical Trials/NCT00666445
NCT00666445
Completed
Not Applicable

Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG) and the Synchronous Neural Interaction™ Test: AD Template Development Study

Orasi Medical, Inc.3 sites in 1 country150 target enrollmentApril 2008

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Alzheimer's Disease
Sponsor
Orasi Medical, Inc.
Enrollment
150
Locations
3
Primary Endpoint
Sensitivity and specificity for test under investigation to diagnose probable Alzheimer's Disease.
Status
Completed
Last Updated
15 years ago

Overview

Brief Summary

This study is designed to test the hypothesis that the Synchronous Neural Interaction™ Test is useful for diagnosing Probable Alzheimer's Disease according to standard criteria. Subjects diagnosed with Alzheimer's Disease as well as age-matched normal control subjects will be evaluated for symptoms of Alzheimer's Disease and those meeting inclusion criteria will undergo a brief, non-invasive scan of brain function using a magnetoencephalography (MEG). The scan itself lasts 1 minute while the subject is asked to stare at a dot projected in front of them on a video screen. Orasi Medical believes that patterns of brain activity measured at rest are indicative of Alzheimer's Disease pathology.

The protocol is amended to add a follow-up assessment for previously enrolled and completed subjects who agree to participate in the follow-up assessment approximately 9 - 15 months after initial study enrollment. Subjects who agree to participate in the follow-up assessment will undergo the same standardized tests and MEG scan procedure as completed in the initial study.

Registry
clinicaltrials.gov
Start Date
April 2008
End Date
December 2009
Last Updated
15 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Subject is between 18 and 90 years of age
  • i. Provide written informed consent for study participation, OR ii. Provide written assent to study participant accompanied by the provision of written informed by the subject's legally authorized representative (LAR); see Section
  • Informed Consent for details of the procedures use to meet these study inclusion criteria
  • Have one of the following clinical diagnoses or conditions:
  • Probable AD according to the NINCDS-ADRDA criteria
  • Possible AD according to the NINCDS-ADRDA criteria
  • Prodromal AD according to criteria described by Dubois \& Albert (2004)
  • Normal control subject

Exclusion Criteria

  • Have a significant non-AD neurological condition including Parkinson's Disease, Vascular Dementia, Lewy Body Dementia or Frontal Temporal Dementia, human immunodeficiency virus, multiple sclerosis, epilepsy, or severe traumatic brain injury.
  • Have dementia due to multiple etiologies (e.g. mixed dementia)
  • Show the presence of prominent disturbances in gait thought to be associated with Parkinsonism.
  • Show prominent changes in personality or social conduct prior to the onset of prominent cognitive dysfunction
  • Have a Modified Hachinski Ischemia Scale score of greater than 4
  • Have a history of primary psychotic disorder (e.g schizophrenia, schizoaffective disorder, delusional disorder) or bipolar disorder
  • Have a lifetime or current history of alcohol or substance abuse/dependence
  • Have had an MRI two weeks prior to completing the MEG scan
  • Have metal braces or pacemaker that may interfere with the MEG scan
  • Are unable to complete the MEG scan procedure

Outcomes

Primary Outcomes

Sensitivity and specificity for test under investigation to diagnose probable Alzheimer's Disease.

Time Frame: Immediately

Study Sites (3)

Loading locations...

Similar Trials